{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:44:13Z","timestamp":1783813453448,"version":"3.55.0"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:00:00Z","timestamp":1419638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine pregnancy outcomes in the partners of male patients with inflammatory joint disease who were or were not exposed to disease\u2010modifying antirheumatic drugs (DMARDs) before conception compared with the outcomes in reference subjects from the general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Linkage of data from a longitudinal observational study of patients with inflammatory joint disease (the Norwegian Disease\u2010Modifying Antirheumatic Drug [NOR\u2010DMARD] registry study) and the Medical Birth Registry of Norway (MBRN) enabled a comparison of pregnancy outcomes in the partners of men with inflammatory joint disease. Outcomes of pregnancies in which the father was exposed to DMARDs within 12 weeks of conception and those in which the father was never exposed to DMARDs were analyzed separately and compared with the outcomes in reference subjects. Potential associations between DMARD exposure and adverse pregnancy outcomes were assessed by logistic regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,796 men with inflammatory joint disease were associated with 2,777 births in the MBRN. In 110 of these births, the father had been exposed to DMARDs within 12 weeks before conception, and in 230 births the father had never been exposed to DMARDs before conception. The DMARDs (monotherapy or combination treatment) to which the fathers were exposed most frequently within 12 weeks of conception were methotrexate (n = 49), sulfasalazine (n = 17), and tumor necrosis factor inhibitors (n = 57). Neither adverse pregnancy outcomes nor occurrence of congenital malformations differed between patients and reference subjects in either group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Preconception paternal exposure to DMARDs was not associated with an increase in adverse pregnancy outcomes. Importantly, no increased risk of congenital malformations was observed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.38919","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T05:21:20Z","timestamp":1416806480000},"page":"296-301","source":"Crossref","is-referenced-by-count":51,"title":["Brief Report: No Excess Risks in Offspring With Paternal Preconception Exposure to Disease\u2010Modifying Antirheumatic Drugs"],"prefix":"10.1002","volume":"67","author":[{"given":"Marianne","family":"Wallenius","sequence":"first","affiliation":[{"name":"Trondheim University Hospital and Norwegian University of Science and Technology Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lie","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Daltveit","sequence":"additional","affiliation":[{"name":"University of Bergen and Norwegian Institute of Public Health Bergen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell \u00c5.","family":"Salvesen","sequence":"additional","affiliation":[{"name":"Lund University, Lund, Sweden, and Norwegian University of Science and Technology Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan F.","family":"Skomsvoll","sequence":"additional","affiliation":[{"name":"Trondheim University Hospital Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syn\u00f8ve","family":"Kalstad","sequence":"additional","affiliation":[{"name":"University Hospital of Northern Norway Troms\u00f8 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se S.","family":"Lexberg","sequence":"additional","affiliation":[{"name":"Vestre Viken\/Drammen Hospital Drammen Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Lillehammer Hospital for Rheumatic Diseases Lillehammer Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"\u00d8stensen","sequence":"additional","affiliation":[{"name":"Trondheim University Hospital Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30210"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24914"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1957"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2000.079006435.x"},{"key":"e_1_2_7_6_1","first-page":"S188","article-title":"A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases","volume":"23","author":"Kvien TK","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_7_1","unstructured":"European Surveillance of Congenital Anomalies EUROCAT. Guide 1.4 chapter 3.3: coding of EUROCAT subgroups of congenital anomalies. URL:http:\/\/www.eurocat\u2010network.eu\/content\/EUROCAT\u2010Guide\u20101.4\u2010Chapter\u20103.3.pdf."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/172395"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket390"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.138"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s003840050093"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2011.626442"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2010.12.001"},{"key":"e_1_2_7_14_1","first-page":"S730","article-title":"Pregnancy outcomes in women exposed to adalimumab: an update on the Autoimmune Diseases in Pregnancy project","volume":"63","author":"Johnson DY","year":"2011","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1351.019"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38919","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:38:09Z","timestamp":1759941489000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,27]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/art.38919"],"URL":"https:\/\/doi.org\/10.1002\/art.38919","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,27]]}}}